Lecia V. Sequist, MD, MPH

Publications

• Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Eng
  21430269
• Mak RH, Digumarthy SR, Muzikansky A, Engelman JA, Shepard JA, Choi NC, Sequist LV.Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Predicting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.Oncologist. 2011;16(3):319
  21339258
• Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R.Activity of IPI-504, a Novel Heat-Shock Protein
  20940188
• Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J
  20979469
• Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP, Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S, Sequist LV, Lee RJ, Isselbacher KJ, Maheswaran S, Haber DA, Toner M.Isolation
  20930119
• Neal JW, Heist RS, Fidias P, Temel JS, Huberman M, Marcoux JP, Muzikansky A, Lynch TJ, Sequist LV.Cetuximab Monotherapy in Patients with Advanced Non-small Cell Lung Cancer After Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy.J T
  20975380
• Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, Lynch TJ, Sequist LV.EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.Neuro Oncology. 2010 Nov;12(11):1193-9.
  20627894
• Heist RS, Fain J, Chinnasami B, Khan W, Molina JR, Sequist LV, Temel JS, Fidias P, Brainerd V, Leopold L, Lynch TJ.Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer.J Thorac Oncol. 2010 Oct;5(10):1637-43.
  20808253
• Neal JW, Sequist LV.Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh.Curr Treat Options Oncol. 2010 Jun;11(1-2):36-44.
  20676809
• Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C, Ananthakrishnan R, Quinn S, Soria JC.Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients
  20479403
• Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, Iafrate AJ.Rapid targeted mut
  20432502
• Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber DA, Maheswaran S.Isolation and characteri
  20424012
• Neal JW, Sequist LV.First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.Clin Adv Hematol Oncol. 2010 Feb;8(2):119-26. Review.
  20386533
• Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA.Preexistence and clon
  20129249
• Neal JW, Sequist LV.Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.Nat Rev Clin Oncol. 2010 Feb;7(2):71-2.
  20118973
• Sequist LV.Protein degradation/chaperone system and histone deacetylase pathway.J Thorac Oncol. 2009 Nov;4(11 Suppl 3):S1077-8.
  19861924
• Sequist LV, Fidias PM, Temel JS, Kolevska T, Rabin MS, Boccia RV, Burris HA, Belt RJ, Huberman MS, Melnyk O, Mills GM, Englund CW, Caldwell DC, Keck JG, Meng L, Jones M, Brown GL, Edelman MJ, Lynch TJ.Phase 1-2a multicenter dose-ranging study of canfosfam
  19701107
• Sequist LV, Fidias P, Heist RS, Ostler P, Muzikansky A, Lynch TJ.Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung cancer.J Thorac Oncol. 2009 Sep;4(9):1170-3.
  19704338
• Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE.Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients:
  19671843
• Pirl WF, Solis J, Greer J, Sequist L, Temel JS, Lynch TJ.Epidermal growth factor receptor tyrosine kinase inhibitors and depression.J Clin Oncol. 2009 Aug 10;27(23):e49-50; author reply e51.
  19597022
• Sequist LV,Engelman JA,Lynch TJ.Toward noninvasive genomic screening of lung cancer patients.J Clin Oncol. 2009 Jun 1;27(16):2589-91.
  19414671
• Sequist LV,Nagrath S,Toner M,Haber DA,Lynch TJ.The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients.J Thorac Oncol. 2009 Mar;4(3):281-3.
  19247082
• Costa DB,Nguyen KS,Cho BC,Sequist LV,Jackman DM,Riely GJ,Yeap BY,Halmos B,Kim JH,Janne PA,Huberman MS,Pao W,Tenen DG,Kobayashi S.Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.Clin Cancer Res. 2008 Nov 1;14(2
  18981003
• Chin TM,Quinlan MP,Singh A,Sequist LV,Lynch TJ,Haber DA,Sharma SV,Settleman J.Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib t
  18980981
• Heist RS,Fidias P,Huberman M,Ardman B,Sequist LV,Temel JS,Lynch TJ.A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer.J Thorac Oncol. 2008 Oct;3(10):1153-8.
  18827612
• Sequist LV,Settleman JE,Ackman JB,Iafrate AJ.Case records of the Massachusetts General Hospital. Case 23-2008. A 26-year-old man with back pain and a mass in the lung.N Engl J Med. 2008 Jul 24;359(4):405-14.
  18650517
• Maheswaran S,Sequist LV,Nagrath S,Ulkus L,Brannigan B,Collura CV,Inserra E,Diederichs S,Iafrate AJ,Bell DW,Digumarthy S,Muzikansky A,Irimia D,Settleman J,Tompkins RG,Lynch TJ,Toner M,Haber DA.Detection of mutations in EGFR in circulating lung-cancer cells
  18596266
• Sequist LV.First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients.J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S143-5. Review.
  18520299
• Lynch TJ Jr,Blumenschein GR Jr,Engelman JA,Espinoza-Delgado I,Govindan R,Hanke J,Hanna NH,Heymach JV,Hirsch FR,Janne PA,Lilenbaum RC,Natale RB,Riely GJ,Sequist LV,Shapiro GI,Shaw A,Shepherd FA,Socinski M,Sorensen AG,Wakelee HA,Weitzman A.Summary statement
  18520291
• Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.First-Line Gefitinib in Patients With Adv
  18458038
• Bradbury PA, Heist RS, Kulke MH, Zhou W, Marshall AL, Miller DP, Su L, Park S, Temel J, Fidias P, Sequist L, Lynch TJ, Wain JC, Shepherd FA, Christiani DC, Liu G.A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic
  18199725
• Sequist LV, Lynch TJ.EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story.Annu Rev Med. 2008;59:429-42. Review.
  17716025
• Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M.Isolation of rare circulating tumour cells in cancer patients by microchip technology.Nature.
  18097410
• Oxnard GR, Fidias P, Muzikansky A, Sequist LV.Non-small cell lung cancer in octogenarians: treatment practices and preferences.J Thorac Oncol. 2007 Nov;2(11):1029-35.
  17975495
• Lynch TJ, Bonomi PD, Butts C, Davies AM, Engelman J, Govindan R, Herbst RS, Heymach JV, Johnson BE, Martins RG, Perez-Soler R, Riely GJ, Sandler AB, Sequist LV, Socinski MA, Wong KK, Hart CS.Novel agents in the treatment of lung cancer: Fourth Cambridge C
  17671145
• Finberg KE, Sequist LV, Joshi VA, Muzikansky A, Miller JM, Han M, Beheshti J, Chirieac LR, Mark EJ, Iafrate AJ.Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar
  17591931
• Sequist LV, Dziadziuszko R.Update on epidermal growth factor receptor inhibitor development in lung cancer.J Thorac Oncol. 2006 Sep;1(7):740-3.
  17409951
• Sequist LV.Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.Oncologist. 2007 Mar;12(3):325-30. Review.
  17405897
• Sequist LV, Bell DW, Lynch TJ, Haber DA.Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.J Clin Oncol. 2007 Feb 10;25(5):587-95. Review.
  17290067
• Sequist LV, Joshi VA, Jänne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJ.Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.Oncologist. 2007 Jan
  17285735
• Sequist LV, Joshi VA, Jänne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ.Epidermal growth factor receptor mutation testing in the care of lung cancer pat
  16857818
• Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jänne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS.Summary statement: novel agents in the treatment of lung ca
  16857812
• Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA.Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged s
  16818686
• Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC, Freedman AS, Mauch P, Schlossman R, Sequist LV, Soiffer RJ, Marshall B, Neuberg D, Ritz J, Nadler LM.Autologous and allogeneic stem cell transplantations for poor-risk chronic lym
  16131571
• Sequist LV, Haber DA, Lynch TJ.Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.Clin Cancer Res. 2005 Aug 15;11(16):5668-70.
  16115901
• Sequist LV, Fidias P.Treatment of advanced non-small cell lung cancer in the elderly.Semin Respir Crit Care Med. 2005 Jun;26(3):289-97.
  16052430
• Sequist LV, Lynch TJ.Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes!.J Clin Oncol. 2003 Sep 1;21(17):3186-8.
  12874267